Nachrichten zur Amgen Inc. Aktie

Is Eli Lilly Stock a Buy?

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and its an element you…

Amgen: Nächste gute Nachricht – AKTIONÄR-Tipp 32 Prozent im Plus

In der jüngeren Vergangenheit konnte Amgen mit verheißungsvollen News zu einem Adipositas-Medikament und einer Dividenden-Erhöhung glänzen (DER AKTIONÄR berichtete). Am…

Amgen Aktie weiter stark - Phase-3-Erfolg und starke Pipeline beflügeln

Kulmbach (www.aktiencheck.de) - Amgen-Aktienanalyse von "Der Aktionär": Martin Mrowka vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Amgen Inc. (ISIN: US0311621009,…

AMGNs Eczema Drug Meets Goal in Two Late-Stage Studies

Data from two more late-stage studies show that treatment with Amgens rocatinlimab improves outcomes in atopic dermatitis indication.…

Take the Zacks Approach to Beat the Markets: NioCorp, AngloGold, Amgen in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the…

1 Dividend Stock Down 30% to Buy and Hold for the Next Decade

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year. Though the drugmaker had performed well since the…

3 Magnificent Growth Stocks to Buy in March

Its often challenging to decide which stocks to invest in. However, some companies look too attractive to pass up. We…

2 Dividend Stocks to Buy for a Lifetime of Passive Income

Dividend investors dont buy shares of companies hoping they will suspend their payouts soon. The longer a corporation maintains its…

Amgen (AMGN) Up 2.9% Since Last Earnings Report: Can It Continue?

Amgen (AMGN) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…

AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Amgen starts two critical late-stage trials for weight loss drug MariTide

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and Eli…

Prediction: 2 Brilliant Vanguard Index Funds Will Continue to Beat the S&P 500 in 2025

The S&P 500 (SNPINDEX: ^GSPC) is widely considered the best gauge for the overall U.S. stock market due to its…

This Could Be the Best GLP-1 Stock to Buy in 2025

The GLP-1 weight loss market is a massive one, with some analysts expecting it to be worth around $200 billion…

Amgen Stock: Why I Still Rate It A Buy

…

These 3 Dow Jones Stocks Are Crushing It in 2025. Are They Still Buys?

How is the Dow Jones Industrial Average (DJINDICES: ^DJI) performing this year? It might depend on whether you view the…

The Zacks Analyst Blog Highlights AbbVie, Amgen, Stryker, Dexcom and Medtronic

AbbVie, Amgen, Stryker, Dexcom and Medtronic are included in this Analyst Blog.…

Drugmaker Amgen to invest $200 million in India site, CEO says

By Rishika Sadam HYDERABAD, India (Reuters) -U.S. drugmaker Amgen will invest about $200 million this year in its new technology…

Amgen plans $200 million investment in India site, CEO says

U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further…

Amgen to invest $200 million in India site, CEO says

HYDERABAD, India (Reuters) -U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern…

Nebulizer Patent Landscape Report 2024: Innovative Developments Fuel Market Growth

Dublin, Feb. 21, 2025 (GLOBE NEWSWIRE) -- The "Nebulizer Patent Landscape Report" report has been added to …

Amgen, Inc. (AMGN) Citis 2025 Virtual Oncology Leadership Summit Conference (Transcript)

…

This Company Just Initiated a Quarterly Dividend: Time to Buy?

Biotech giant Renegeron Pharmaceuticals (NASDAQ: REGN) reported its fourth-quarter and full-year 2024 earnings on Feb. 4. The companys results were…

Want Decades of Passive Income? Buy This ETF and Hold It Forever.

Who doesnt want passive income? Even Warren Buffett has extolled it, reportedly saying, "If you dont find a way to…

Amgen, Inc. (AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call Transcript

…

Genomic Data Analysis and Interpretation Market Research 2025-2033: Syngenta Group Leads, Followed by Amgen, Monsanto (Bayer), and Illumina

Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The "Genomic Data Analysis and Interpretation Market Opportunities and Strategies to…

Amgens EVP Jonathan Graham sells $7.34 million in stock By Investing.com

Amgens EVP Jonathan Graham sells $7.34 million in stock…

Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move

Investing in stocks that arent performing well can be a good move, but only if there are good reasons to…

Better High-Yield Dividend Stock: Pfizer vs. Merck

Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical…

3 Fabulous Dividend Stocks to Buy in February

February is the shortest month, but that doesnt mean income investors dont have much time to find great stocks. Three…

Amgen SVP Nancy Grygiel sells stock for $483,807 By Investing.com

Amgen SVP Nancy Grygiel sells stock for $483,807…

The Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex

Amgen, CRISPR, Moderna, Sarepta and Vertex are included in this Analyst Blog.…

GNW-News: Accumulus Synergy liefert das erste digital erstellte Dossier der Branche in fast zwei Dutzend Länder gleichzeitig

^BURLINGAME, Kalifornien, Feb. 05, 2025 (GLOBE NEWSWIRE) Accumulus Synergy(?Accumulus") hat in einem branchenweit einmaligen Moment den bahnbrechendenZulassungsantrag von Amgen…

dpa-AFX ProFeed